Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 18;16(12):2378-2392.
doi: 10.1093/ckj/sfad239. eCollection 2023 Dec.

Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients

Collaborators, Affiliations
Review

Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients

Gaye Hafez et al. Clin Kidney J. .

Abstract

There is growing evidence that chronic kidney disease (CKD) is an independent risk factor for cognitive impairment, especially due to vascular damage, blood-brain barrier disruption and uremic toxins. Given the presence of multiple comorbidities, the medication regimen of CKD patients often becomes very complex. Several medications such as psychotropic agents, drugs with anticholinergic properties, GABAergic drugs, opioids, corticosteroids, antibiotics and others have been linked to negative effects on cognition. These drugs are frequently included in the treatment regimen of CKD patients. The first review of this series described how CKD could represent a risk factor for adverse drug reactions affecting the central nervous system. This second review will describe some of the most common medications associated with cognitive impairment (in the general population and in CKD) and describe their effects.

Keywords: adverse drug reaction; chronic kidney disease; cognitive impairment; drug prescription; medications.

PubMed Disclaimer

Conflict of interest statement

The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Figures

Graphical Abstract
Graphical Abstract
Figure 1:
Figure 1:
The most common medications with negative impacts on cognition in the general population.

References

    1. Berger I, Wu S, Masson Pet al. Cognition in chronic kidney disease: a systematic review and meta-analysis. BMC Med 2016;14:206. 10.1186/s12916-016-0745-9 - DOI - PMC - PubMed
    1. Strassels SA. Cognitive effects of opioids. Curr Pain Headache Rep 2008;12:32–6. 10.1007/s11916-008-0007-4 - DOI - PubMed
    1. Liabeuf S, Laville M.. Drug prescription in patients with chronic kidney disease: a true challenge. Nephrol Dial Transplant 2021;36:385–6. 10.1093/ndt/gfaa164 - DOI - PubMed
    1. Langmead CJ, Watson J, Reavill C.. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol Ther 2008;117:232–43. 10.1016/j.pharmthera.2007.09.009 - DOI - PubMed
    1. Santiago LJ, Abrol R.. Understanding G protein selectivity of muscarinic acetylcholine receptors using computational methods. Int J Mol Sci 2019;20:5290. 10.3390/ijms20215290 - DOI - PMC - PubMed